Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces 'first patient' randomised in EVIDENCES-X™ Phase II(b) clinical trial of Saroglitazar Mg in NASH

Posted On: 2021-10-22 17:48:11 (Time Zone: IST)


Zydus, a leading discovery based, global pharmaceutical company today announced that it has randomised the First patient into the Phase 2(b) Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled clinical trial to evaluate Efficacy and Safety of Saroglitazar Magnesium in subjects with Non-Alcoholic Steatohepatitis and Fibrosis. Zydus had earlier received permission from the USFDA [ClinicalTrials.gov Identifier: NCT05011305].

The EVIDENCES-X™ liver biopsy driven Phase 2(b) trial will be led by Prof. Naga Chalasani, M.D., Interim Chair, Department of Medicine, Indiana University School of Medicine and Prof. Arun J. Sanyal, M.D., Division of Gastroenterology, Virginia Commonwealth University as co-Principal Investigators. The EVIDENCES-X™ trial will randomise 240 subjects in a 1:1:1 ratio to Saroglitazar 2 mg, Saroglitazar 4 mg or Placebo and study the primary endpoint "Resolution of steatohepatitis with no worsening of fibrosis" over a period of 76 weeks. The secondary end-points will include improvement in liver fibrosis with no increase in NAS for ballooning, inflammation or steatosis, 2 points improvement in NAS, Improvement in steatosis, ballooning, inflammation and fibrosis from liver biopsy, Histological score changes in steatosis, ballooning, inflammation and fibrosis.

Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders. Experts estimate that about 25% of adults have NAFLD worldwide (K Nonalcoholic steatohepatitis: global impact and clinical consequences, Younossi et al., Endocr Connect. 2021 Oct 7;10(10):R240-R247. doi: 10.1530/EC-21-0048.). NASH is a progressive form of NAFLD and is characterised by histologic evidence of hepatic steatosis, lobular inflammation, hepatocyte ballooning with or without pericellular fibrosis, and/or MalloryDenk bodies, which can progress to liver cirrhosis, liver cancer and need for liver transplant or death. Experts estimate about 5 - 20 % of adults worldwide have NASH placing significant clinical, economical, and health-related quality of life (HRQoL) burden for treating this liver disease (Source: Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. Jamie O-Hare et. al., JHEP Reports 2020 vol. 2 j 100142). Analysts estimate the global market for Non-alcoholic steatohepatitis (NASH) treatment will reach $27 billion in 2029 (Source: Globaldata).

Speaking on the new development, Chairman of Cadila Healthcare Ltd., Mr. Pankaj R. Patel said, "As there is currently no drug approved for the treatment of NASH in the USA, this life threatening liver disease is a high unmet medical need. We are committed to develop novel therapeutics for patients living with liver diseases and fibrosis. We stand encouraged that the findings from the earlier EVIDENCES-IV Phase 2 clinical study have been published as original article by Samer et al along with the editorial by Prof. Sven Francque, M.A. a leading hepatologist from Belgium in the October edition of Hepatology, the Journal of American Association for the Study of Liver Diseases (AASLD)".

NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver, which can progress to liver cirrhosis, need for liver transplant or death. Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA). The USFDA has granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC. The European Medicines Agency (EMA) has designated "Saroglitazar magnesium" with Orphan status for Treatment of Primary Biliary Cholangitis.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 502.40 as compared to the previous close of Rs. 510.20. The total number of shares traded during the day was 80723 in over 1943 trades.

The stock hit an intraday high of Rs. 517.70 and intraday low of 501.00. The net turnover during the day was Rs. 41003473.00.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

JSPL records a 10% YoY production increase in November 2021

KPI Global Infrastructure Ltd receives orders for 2.70 MWdc solar power project

Imagicaaworld to reopen its Water Park from 17th December 2021

Hindustan Zinc Ltd board approves interim dividend of Rs. 18

Spice Money further bolsters leadership team to fast-track the growth

Noida International Airport awards 30-year concession to Indian Oil Skytanking Ltd for setting up the fuel farm and hydrant system

ICICI Bank offers instant overdraft facility to sellers registered on Flipkart

Canara Bank enters into MOU with Toyota Kirloskar Motor Pvt Ltd

Gulshan Polyols Ltd signs long-term offtake agreement with OMCs

California Software Company Ltd to acquire majority stake in Pratsware

NHPC Ltd board approves proposal for monetization of asset of the Company

Rajshree Sugars and Chemicals Ltd updates on debt retructuring

TA'ZIZ and Reliance Launch Strategic Joint Venture for $2 Billion Chemicals Projects in Ruwais

Polyplex Corporation Ltd's subsidiary commissions new BOPP Film Line

Brightcom Group Limited to acquire MediaMint

Praj's BIOSYRUP® to enable year-round production of ethanol to boost to the sugar sector

TCS BaNCS™ recognized as a Large Player in the Now Tech Report for Digital Wealth Management Platforms

Modern Converters Ltd is now Modern Engineering and Projects Limited

Texmaco Rail and Engineering Ltd announces successful completion of Rights Issue

Shalby Ltd arm increases stake in Singapore arm

Gulshan Polyols Ltd updates on Ethanol offtake by OMCs in Assam

Madras High Court stays winding up order against SpiceJet Ltd for 3 weeks, asks company to deposit $5 mn

ADF Foods bags exclusive distribution rights of Patanjali products across Western Europe and UK

Prakash Industries Ltd secures Long-Term Coal Linkages for Captive Power Plant

Praveg Communications India Ltd applies for license to start 'PRAVEG TV'

Bloom Dekor Ltd updates on freezing of current account by PNB

Indo Us Bio Tech Limited allots 12,13,598 bonus shares

Aurionpro selected as Solution Provider by the State Bank of India for Kanpur Metro Project

Financial Times and Infosys announce Strategic Digital Collaboration to Enhance Immersive Journalism

Nestle India Receives Approval Under Production Linked Scheme

Mawana Sugars Ltd to make contribution of upto Rs. 3 crore to political parties

Dilip Buildcon Ltd emerges L1 bidder for tender floated by South Eastern Coalfields Limited

Saboo Sodium Chloro Ltd's FMCG division to launch two new products

APL Apollo Tubes Ltd stands at 56th Percentile of the S&P Global CSA 2021

TAKE Solutions announces appointment of Chief Operating Officer

Route Mobile Limited Launches Payment as a Service

Foods & Inns Limited receives approval under PLI scheme of Ministry of Food Processing Industries

State Bank of India chooses Intellect Wealth Qube® for its Digital Wealth Transformation

Winners of NCPEDP - Mindtree Helen Keller Awards 2021 announced

Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East

Niti Aayog proposes to RBI to categorise loans to electric vehicles as Priority Sector Lending segment

Tanla and Vi sign partnership to deploy patented block-chain enabled Wisely Platform

MyGov India & Chingari App discuss major digital transformations for the nation at Azadi ka Digital Mahotsav

Tata Elxsi recognized as a 'Leader' and specialized ER&D Service Provider across multiple industries in Zinnov Zones 2021 annual ratings

Industrial Investment Trust Limited to sell stake in Future Generali India Life Insurance Company Ltd

CEBBCO receives order for supply of ISO Containers

Karnataka Bank partners with Toyota Kirloskar Motor Private Limited to extend retail vehicle finance support to its customers

Prakash Industries Limited's surplus land attached by ED

HDFC Securities guides in securing the investors' financial future with InvestPlus!

Tata Steel deploys its first Bio-Fuel powered ship for imported raw material transportation


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020